The Bill & Melinda Gates Foundation has committed $40 million in equity investment and $10 million in grant funding to Vir Biotechnology for the development of therapies against HIV and Malaria, Vir announced Friday. Read the full Press Release here.
Program Areas: HIV
Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and More
XCONOMY SAN FRANCISCO – Vir Biotechnology has joined the public markets, raising $142.9 million to support clinical tests of its infectious disease drugs. Read the full press release here.
LumiraDx develops point-of-care diagnostics solutions on a portable, cloud-connected reader using finger-prick blood samples tested on disposable, microfluidic strips. The company is working to achieve lab-quality performance and health-IT integration at point-of–care settings globally. The foundation invested in the company Read More
The Guardian: ‘The earlier you go, the longer you live’: HIV self-testing in South Africa
By Rebecca Ratcliffe April 16, 2018 David* is perched on a stool, staring at the table in front of him. On it, a small testing stick stands in a cylinder of liquid. “I’ve never tested before, so I thought I Read More
Zyomyx is a private biotechnology company specializing in HIV CD4 diagnostics.
Vir Biotechnology is a newly-formed company based in San Francisco focused on finding innovative solutions to unmet needs in infectious disease.
The foundation invested in OraSure to secure a reduced price for the saliva-based HIV self-test OraQuick.
Mylan Laboratories, along with Aurobindo Pharma, received support from the foundation to expand the distribution of a single-pill HIV treatment containing dolutegravir to low- and middle-income populations at a low price.
Kymab has developed a proprietary mouse platform which contains the full range of human antibodies, leading to faster discovery of prophylactic and therapeutic monoclonal antibodies.
The foundation invested in Intarcia to help prevent the spread of HIV in Sub-Saharan Africa and other areas where the HIV epidemic is most severe.